Research programme: autophagy inhibitors - Astellas Pharma/Cancer Research UKAlternative Names: Cancer therapeutics - Astellas Pharma/Cancer Research UK
Latest Information Update: 13 Aug 2014
At a glance
- Originator Cancer Research UK
- Developer Astellas Pharma; Cancer Research UK
- Mechanism of Action Autophagy inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Pancreatic cancer
Most Recent Events
- 08 Aug 2014 Early research in Pancreatic cancer in United Kingdom (unspecified route)